|
de Jong, J L; Farner, N L; Javorsky, B R et al. (1998) Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy. Clin Cancer Res 4:1287-96
|
|
Nicolet, C M; Surfus, J M; Hank, J A et al. (1998) Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy. Cancer Immunol Immunother 46:327-37
|
|
de Jong, J L; Farner, N L; Sondel, P M (1998) Distinctions in lymphocyte responses to IL-2 and IL-15 reflect differential ligand binding interactions with the IL-2Rbeta chain and suggest differential roles for the IL-2Ralpha and IL-15Ralpha subunits. Cytokine 10:920-30
|
|
Nicolet, C M; Siegel, D H; Surfus, J E et al. (1997) TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines. Tumour Biol 18:356-66
|
|
Helfand, S C; Soergel, S A; Donner, R L et al. (1994) Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. J Immunother Emphasis Tumor Immunol 16:188-97
|
